logo
GTII logo

GTII
Green Thumb Industries

Partnerships With Magnolia Bakery And DoorDash Will Expand Market Reach

WA
Consensus Narrative from 8 Analysts
Published
January 22 2025
Updated
March 12 2025
Share
WarrenAI's Fair Value
CA$20.08
51.0% undervalued intrinsic discount
12 Mar
CA$9.84
Loading
1Y
-36.4%
7D
-4.4%

Key Takeaways

  • Strategic investment in new products, partnerships, and key growth markets aims to drive revenue growth and capture new consumer demographics.
  • Expansion in cultivation and operational capabilities in newly legalized states seeks to meet demand and improve margins through efficiencies.
  • Uncertain cannabis reform and regulatory dependence, competitive pressures, and rising marketing expenses may impact revenue growth, profitability, and market stability for Green Thumb Industries.

Catalysts

About Green Thumb Industries
    Manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States.
What are the underlying business or industry changes driving this perspective?
  • Green Thumb's strategic focus on cash flow and disciplined capital allocation, including share repurchase programs and strategic M&A, is expected to strengthen their balance sheet and drive long-term shareholder returns. This focus should positively impact future earnings as the company reduces debt and leverages new capital effectively.
  • The company's investment in innovative products such as THC beverages and aggressive partnerships like the one with Magnolia Bakery and DoorDash are likely to increase revenue by capturing new consumer demographics and expanding their market reach through non-traditional channels.
  • The expansion into and operational excellence in key growth markets such as Ohio, New Jersey, and New York is anticipated to drive significant revenue growth, especially as these states develop their legal cannabis markets and the company capitalizes on its leading market share in places like Ohio.
  • The company's strategic investment in expanding cultivation and production capabilities, particularly in newly legalized states, positions it to meet increasing consumer demand and potentially improve net margins through economies of scale and operational efficiencies.
  • Green Thumb's development of its omnichannel retail strategy, including e-commerce and home delivery, should bolster revenue growth by making their products more accessible and convenient for consumers, thereby enhancing the overall consumer experience and brand loyalty.

Green Thumb Industries Earnings and Revenue Growth

Green Thumb Industries Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?
  • Analysts are assuming Green Thumb Industries's revenue will grow by 4.9% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 6.4% today to 17.1% in 3 years time.
  • Analysts expect earnings to reach $225.0 million (and earnings per share of $0.62) by about March 2028, up from $73.1 million today. The analysts are largely in agreement about this estimate.
  • In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 17.0x on those 2028 earnings, down from 21.8x today. This future PE is lower than the current PE for the CA Pharmaceuticals industry at 21.8x.
  • Analysts expect the number of shares outstanding to decline by 0.48% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 5.82%, as per the Simply Wall St company report.

Green Thumb Industries Future Earnings Per Share Growth

Green Thumb Industries Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?
  • Uncertain federal cannabis reform under the new administration may limit market expansion opportunities, potentially impacting future revenue growth.
  • Continued pricing pressure in many markets, due to supply-demand imbalances and competition from unregulated products, could erode profitability and reduce net margins.
  • The reliance on regulatory change for THC distribution expansion signals execution risk, which may not materialize as expected, affecting revenue streams.
  • Increased marketing expenses aimed at building brand awareness may not yield immediate returns, potentially increasing SG&A and pressuring EBITDA margins.
  • Competitor financial struggles and operational challenges in existing markets like New York could pose risks to Green Thumb's market share and earnings stability.

Valuation

How have all the factors above been brought together to estimate a fair value?
  • The analysts have a consensus price target of CA$20.084 for Green Thumb Industries based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CA$25.84, and the most bearish reporting a price target of just CA$13.92.
  • In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $1.3 billion, earnings will come to $225.0 million, and it would be trading on a PE ratio of 17.0x, assuming you use a discount rate of 5.8%.
  • Given the current share price of CA$9.73, the analyst price target of CA$20.08 is 51.6% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

How well do narratives help inform your perspective?

Disclaimer

Warren A.I. is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by Warren A.I. are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that Warren A.I.'s analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Analyst Price Target Fair Value
CA$20.1
51.0% undervalued intrinsic discount
Future estimation in
PastFuture-54m1b20162018202020222024202520262028Revenue US$1.3bEarnings US$225.0m
% p.a.
Decrease
Increase
Current revenue growth rate
4.96%
Pharma revenue growth rate
0.43%